Blacksmith Medicines Granted U.S. Patent Covering Antibacterial Compounds Targeting LpxCblacksmithmed2025-06-30T19:18:24-07:0007.01.2025|
Blacksmith Medicines Announces Presentation at AACR Annual Meeting 2025blacksmithmed2025-04-29T07:02:01-07:0004.29.2025|
Blacksmith Medicines Presents the Discovery and Chemical Structure of FG-2101, a Novel Antibiotic Candidate Targeting LpxC, at the American Chemical Society (ACS) National Meetingblacksmithmed2025-03-26T07:11:34-07:0003.26.2025|
Blacksmith Medicines to Present Preclinical Oncology Data at 8th DDR Inhibitors Summitblacksmithmed2025-01-27T07:59:50-08:0001.27.2025|
Blacksmith Medicines To Highlight Preclinical Oncology Data Demonstrating a Potent and Selective FEN1 Inhibitor Has Synergy with Multiple DDR Drug Classes at AACR Annual Meeting 2024blacksmithmed2024-04-09T12:23:24-07:0004.10.2024|
Blacksmith Medicines to Present at the 23rd Annual Needham Healthcare Conferenceblacksmithmed2024-04-02T16:19:25-07:0004.03.2024|
Blacksmith Medicines to Present at the Gordon Research Conference on New Antibacterial Discovery and Developmentblacksmithmed2024-03-19T06:59:20-07:0003.19.2024|
Blacksmith Medicines Announces Upcoming Presentation at AACR Annual Meeting 2024blacksmithmed2024-03-06T07:00:33-08:0003.06.2024|
Blacksmith Medicines Announces $3.3M in Funding from NIAID to Support Clinical Trial Manufacturing of Novel Antibioticblacksmithmed2024-02-20T10:03:06-08:0002.21.2024|
Blacksmith Medicines and Zoetis Announce Research Collaboration for Novel Animal Health Antibioticsblacksmithmed2024-02-13T09:36:54-08:0002.14.2024|
